Commentary: Does Lithium Deserve a Place in the Treatment Against COVID-19? A Preliminary Observational Study in Six Patients, Case Report

by Christopher E. Rudd, Christopher E. Rudd, Christopher E. Rudd
Published 2020-12-01

GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response

by Christopher E. Rudd, Christopher E. Rudd, Christopher E. Rudd
Published 2020-06-01

How the Discovery of the CD4/CD8-p56lck Complexes Changed Immunology and Immunotherapy

by Christopher E. Rudd, Christopher E. Rudd, Christopher E. Rudd
Published 2021-03-01

Glycogen Synthase Kinase 3 Inactivation Compensates for the Lack of CD28 in the Priming of CD8+ Cytotoxic T-Cells: Implications for anti-PD-1 Immunotherapy

by Alison Taylor, Christopher E. Rudd, Christopher E. Rudd, Christopher E. Rudd, Christopher E. Rudd
Published 2017-12-01

CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy

by Monika C. Brunner-Weinzierl, Christopher E. Rudd, Christopher E. Rudd
Published 2018-11-01

Programmed cell death 1 ligand (PD-L1) on T cells generates Treg suppression from memory.

by Alexandra Kazanova, Christopher E Rudd
Published 2021-05-01

Glycogen synthase kinase 3 (GSK-3) controls T-cell motility and interactions with antigen presenting cells

by Alison Taylor, Christopher E. Rudd
Published 2020-03-01

Diverse mechanisms regulate the surface expression of immunotherapeutic target CTLA-4

by Helga eSchneider, Christopher E. Rudd
Published 2014-12-01

Immune adaptor SKAP1 acts a scaffold for Polo-like kinase 1 (PLK1) for the optimal cell cycling of T-cells

by Monika Raab, Klaus Strebhardt, Christopher E. Rudd
Published 2019-07-01

Immune adaptor protein SKAP1 (SKAP-55) forms homodimers as mediated by the N-terminal region

by Monika Raab, Klaus Strebhardt, Christopher E. Rudd
Published 2018-12-01

Small Molecule Inhibition of GSK-3 Specifically Inhibits the Transcription of Inhibitory Co-receptor LAG-3 for Enhanced Anti-tumor Immunity

by Christopher E. Rudd, Kittiphat Chanthong, Alison Taylor
Published 2020-02-01

Correction: CTLA-4 Activation of Phosphatidylinositol 3-Kinase (PI 3-K) and Protein Kinase B (PKB/AKT) Sustains T-Cell Anergy without Cell Death

by Helga Schneider, Elke Valk, Rufina Leung, Christopher E. Rudd
Published 2009-01-01

Correction: CTLA-4 Activation of Phosphatidylinositol 3-Kinase (PI 3-K) and Protein Kinase B (PKB/AKT) Sustains T-Cell Anergy without Cell Death.

by Helga Schneider, Elke Valk, Rufina Leung, Christopher E. Rudd
Published 2009-01-01

CTLA-4 activation of phosphatidylinositol 3-kinase (PI 3-K) and protein kinase B (PKB/AKT) sustains T-cell anergy without cell death.

by Helga Schneider, Elke Valk, Rufina Leung, Christopher E Rudd
Published 2008-01-01

GTPase-activating protein Rasal1 associates with ZAP-70 of the TCR and negatively regulates T-cell tumor immunity

by Youg Raj Thaker, Monika Raab, Klaus Strebhardt, Christopher E. Rudd
Published 2019-10-01

Aiming for the Sweet Spot: Glyco-Immune Checkpoints and γδ T Cells in Targeted Immunotherapy

by Margarita Bartish, Sonia V. del Rincón, Sonia V. del Rincón, Christopher E. Rudd, Christopher E. Rudd, H. Uri Saragovi, H. Uri Saragovi, H. Uri Saragovi
Published 2020-09-01

LFA-1 activates focal adhesion kinases FAK1/PYK2 to generate LAT-GRB2-SKAP1 complexes that terminate T-cell conjugate formation

by Monika Raab, Yuning Lu, Karsten Kohler, Xin Smith, Klaus Strebhardt, Christopher E. Rudd
Published 2017-07-01

Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy.

by Janna Krueger, Francois Santinon, Alexandra Kazanova, Mark E Issa, Bruno Larrivee, Richard Kremer, Catalin Milhalcioiu, Christopher E Rudd
Published 2021-01-01

Non-redundant activity of GSK-3α and GSK-3β in T cell-mediated tumor rejection

by Lynette Steele, Aarren J. Mannion, Gary Shaw, Kenneth A. Maclennan, Graham P. Cook, Christopher E. Rudd, Alison Taylor
Published 2021-06-01

Adaptor SKAP-55 binds p21 activating exchange factor RasGRP1 and negatively regulates the p21-ERK pathway in T-cells.

by Helga Schneider, Hongyan Wang, Monika Raab, Elke Valk, Xin Smith, Matt Lovatt, Zhonglin Wu, Braudel Maqueira-Iglesias, Klaus Strebhardt, Christopher E Rudd
Published 2008-03-01